Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study-Reference-Cited by-同舟云学术

Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study

Published:2022-07 Issue:7 Volume:9 Page:e480-e492
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Passamonti Francesco,Palandri Francesca,Saydam Guray,Callum Jeannie,Devos Timothy,Guglielmelli Paola,Vannucchi Alessandro M,Zor Evren,Zuurman Mike,Gilotti Geralyn,Zhang Yifan,Griesshammer Martin

Funder

Novartis AG

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Hematology

Reference28 articles.

1. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management;Tefferi;Am J Hematol,2020

2. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs;Emanuel;J Clin Oncol,2012

3. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia;Passamonti;Am J Med,2004

4. Thromboembolic events in polycythemia vera;Griesshammer;Ann Hematol,2019

5. Mortality and causes of death of patients with polycythemia vera: analysis of the reveal prospective, observational study;Stein;Blood,2020

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between JAK2V617F variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasms;Irish Journal of Medical Science (1971 -);2024-08-14

2. Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians;Clinical Lymphoma Myeloma and Leukemia;2024-08

3. The evolving landscape of polycythemia vera therapies;Expert Opinion on Pharmacotherapy;2024-07-23

4. Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature;Expert Opinion on Pharmacotherapy;2024-07-02

5. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia;American Journal of Hematology;2024-06-06